Procalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT)
Authors:
Open Access
- 30 April 2025
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-13
Abstract
Procalcitonin is a 14.5 kDa protein used clinically as a marker of sepsis and therapeutic response to antibiotic therapy. However, its utility in critically ill patients with either acute kidney injury (AKI) or end-stage kidney disease (ESKD) who require continuous kidney replacement therapy (CKRT) is unknown. The aim of this study was to determine if plasma levels of procalcitonin could reliably distinguish septic from nonseptic status in patients with AKI or ESKD prior to or during CKRT. Procalcitonin concentrations were measured in plasma of 41 critically ill septic or non-septic subjects with AKI or ESKD prior to CKRT (pre-CKRT) and on days 1, 2, and 3 of CKRT in this retrospective cohort study (n = 111 total plasma measurements). Continuous venovenous hemodialysis was the modality of CKRT in these patients. Sepsis status was stringently defined based on culture results. Effluent procalcitonin levels were ascertained on days 1, 2, and 3 of CKRT to assess the clearance of procalcitonin and effects on plasma levels. 92% (66/72) of the plasma procalcitonin measurements among nonseptic patients with either AKI or ESKD were ≥ 0.5 ng/mL (the diagnostic threshold beyond which bacterial infection is very likely). Prior to CKRT initiation, procalcitonin levels were (median (IQR), ng/mL) 5.6 (1.5–18.9) in nonseptic AKI and 58.1 (6.9–195.5) in septic AKI (P = 0.03) and were 3.3 (1.2–8.3) in nonseptic ESKD and 3.7 (1.4–209.8) in septic ESKD (P = 0.79). However, despite being significantly elevated in septic patients with AKI, substantial overlap among procalcitonin levels was present and ROC curve analysis found no cut point that could reliably separate septic from nonseptic patients. Effluent procalcitonin levels were consistently ~ 20% of plasma levels throughout the course of CKRT (i.e., sieving coefficient was 0.2) suggesting that clearance occurs during therapy. However, plasma procalcitonin levels did not significantly decline during CKRT in either AKI or ESKD. Procalcitonin levels are markedly elevated in nonseptic critically ill patients with either AKI or ESKD and do not effectively distinguish sepsis from nonseptic status prior to or during CKRT. We conclude that procalcitonin testing should be avoided in critically ill patients with kidney failure since results are nonspecific in this population.Keywords
All Related Versions
Funding Information
- Baxter Investigator Initiated Grant Funding
- Kuzell Foundation
This publication has 55 references indexed in Scilit:
- Case mix, outcome and activity for patients admitted to intensive care units requiring chronic renal dialysis: a secondary analysis of the ICNARC Case Mix Programme DatabaseCritical Care, 2007
- Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgeryThe Lancet, 2005
- Outcome of Patients With End-Stage Renal Disease Admitted to the Intensive Care UnitMayo Clinic Proceedings, 2004
- Plasma cytokine levels predict mortality in patients with acute renal failureKidney International, 2004
- Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failureCritical Care, 2003
- Procalcitonin and Proinflammatory Cytokine Clearance during Continuous Venovenous Haemofiltration in Septic PatientsAnaesthesia and Intensive Care, 2002
- PLASMA CONCENTRATIONS AND CLEARANCE OF PROCALCITONIN DURING CONTINUOUS VENO-VENOUS HEMOFILTRATION IN SEPTIC PATIENTSShock, 2001
- Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients2000
- Mortality caused by sepsis in patients with end-stage renal disease compared with the general populationKidney International, 2000
- Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter.1975